Latest Insider Transactions at Avidity Biosciences, Inc. (RNA)
This section provides a real-time view of insider transactions for Avidity Biosciences, Inc. (RNA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Avidity Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Avidity Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
911
-1.78%
|
$27,330
$30.24 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-19.96%
|
$640,000
$32.88 P/Share
|
|
Jun 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+16.64%
|
$280,000
$14.22 P/Share
|
|
Jun 10
2025
|
Carsten Boess Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Noreen Henig Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Arthur A Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+25.4%
|
-
|
|
Jun 10
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Simona Skerjanec Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Troy Edward Wilson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+8.79%
|
-
|
|
Jun 10
2025
|
Jean Jinsun Kim Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 10
2025
|
Tamar Thompson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,692
+50.0%
|
-
|
|
Jun 02
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.48 P/Share
|
|
Jun 02
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.4 P/Share
|
|
May 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-5.27%
|
$158,625
$27.83 P/Share
|
|
Apr 01
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+4.82%
|
$88,125
$15.68 P/Share
|
|
Mar 20
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,780
-12.81%
|
$365,180
$31.06 P/Share
|
|
Mar 20
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,540
-9.35%
|
$977,740
$31.06 P/Share
|
|
Mar 20
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,578
-11.62%
|
$296,918
$31.06 P/Share
|
|
Mar 20
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
7,778
-7.41%
|
$241,118
$31.06 P/Share
|
|
Mar 20
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,935
-7.58%
|
$245,985
$31.06 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-17.86%
|
$600,000
$30.13 P/Share
|
|
Mar 11
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+15.15%
|
$280,000
$14.22 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$170,375
$29.41 P/Share
|
|
Mar 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$82,250
$14.7 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,875
-10.41%
|
$188,000
$32.16 P/Share
|
|
Feb 03
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+9.43%
|
$94,000
$16.65 P/Share
|
|
Jan 22
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
5,629
-10.02%
|
$168,870
$30.16 P/Share
|
|
Jan 21
2025
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,287
-1.53%
|
$92,036
$28.59 P/Share
|
|
Jan 21
2025
|
Arthur A Levin Director |
SELL
Open market or private sale
|
Direct |
1,872
-12.62%
|
$52,416
$28.6 P/Share
|
|
Jan 21
2025
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
10,397
-1.51%
|
$291,116
$28.59 P/Share
|
|
Jan 21
2025
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,672
-2.94%
|
$158,816
$28.6 P/Share
|
|
Jan 21
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
2,959
-1.38%
|
$82,852
$28.6 P/Share
|
|
Jan 21
2025
|
Steven George Hughes Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,947
-2.31%
|
$110,516
$28.6 P/Share
|
|
Jan 21
2025
|
Kathleen P. Gallagher Chief Program Officer |
SELL
Open market or private sale
|
Direct |
3,782
-2.14%
|
$105,896
$28.59 P/Share
|
|
Jan 06
2025
|
W. Michael Flanagan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+20.38%
|
-
|
|
Jan 06
2025
|
Teresa Mc Carthy Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+18.82%
|
-
|
|
Jan 06
2025
|
Sarah Boyce President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
82,500
+19.17%
|
-
|
|
Jan 06
2025
|
Michael F Mac Lean Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+18.81%
|
-
|
|
Jan 06
2025
|
John B Moriarty Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+33.33%
|
-
|
|
Jan 06
2025
|
Steven George Hughes Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+22.45%
|
-
|
|
Jan 06
2025
|
Eric Mosbrooker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.03%
|
-
|
|
Jan 06
2025
|
Kathleen P. Gallagher Chief Program Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.42%
|
-
|
|
Jan 06
2025
|
Charles Calderaro Iii Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
Dec 18
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.86%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
Sarah Boyce President and CEO |
SELL
Open market or private sale
|
Direct |
31,855
-10.72%
|
$1,019,360
$32.66 P/Share
|
|
Dec 18
2024
|
Michael F Mac Lean Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,151
-11.85%
|
$356,832
$32.66 P/Share
|
|
Dec 18
2024
|
W. Michael Flanagan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,742
-14.92%
|
$407,744
$32.66 P/Share
|
|
Dec 16
2024
|
Teresa Mc Carthy Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
25,000
-21.01%
|
$825,000
$33.26 P/Share
|